Neo-adjuvant radiation therapy provides a survival advantage in T3-T4 nodal positive gastric and gastroesophageal junction adenocarcinoma: a SEER database analysis

Table 2 Results of multivariate Cox analysis for overall survival and cause-specific survival in different subgroups

Variable	N	Overall survival			Cause-specific survival
Variable	N	HR	95% CI	P	HR	95% CI	P
T_1–2N⁻ subgroup
RT
no NRT	712	Ref.			Ref.
NRT	474	1.28	0.98–1.67	0.073	1.32	0.98–1.8	0.071
Lauren classification
Intestinal	852	Ref.			Ref.
Diffuse	267	1.03	0.8–1.34	0.815	1.01	0.75–1.35	0.958
Unclassified	67	0.82	0.55–1.23	0.34	0.69	0.42–1.14	0.146
T stage
T1	339	Ref.			Ref.
T2	847	1.41	1.13–1.76	0.002	1.68	1.3–2.18	< 0.001
T_1–2N⁺ subgroup
RT
no NRT	1407	Ref.			Ref.
NRT	837	1.29	1.11–1.5	< 0.001	1.29	1.1–1.52	0.002
Lauren classification
Intestinal	1579	Ref.			Ref.
Diffuse	538	1.24	1.08–1.43	0.002	1.27	1.1–1.48	0.001
Unclassified	127	0.92	0.71–1.17	0.484	0.99	0.76–1.28	0.946
T stage
T1	213	Ref.			Ref.
T2	2031	1.28	1.04–1.57	0.022	1.42	1.11–1.8	0.005
N stage
N1	1680	Ref.			Ref.
N2	422	1.73	1.51–1.99	< 0.001	1.84	1.59–2.13	< 0.001
N3	142	2.27	1.83–2.82	< 0.001	2.32	1.83–2.93	< 0.001
T_3–4N⁻ subgroup
RT
no NRT	185	Ref.
NRT	169	0.76	0.5–1.17	0.216	0.71	0.44–1.14	0.157
Lauren classification
Intestinal	252	Ref.
Diffuse	82	1.4	0.97–2.02	0.074	1.42	0.96–2.09	0.08
Unclassified	20	0.62	0.29–1.32	0.213	0.71	0.31–1.59	0.4
T stage
T3	272	Ref.
T4	82	2.28	1.52–3.41	< 0.001	2.29	1.49–3.51	< 0.001
T_3–4N⁺ subgroup
RT
no NRT	984	Ref.
NRT	504	0.79	0.66–0.95	0.01	0.75	0.62–0.92	0.004
Lauren classification
Intestinal	912	Ref.
Diffuse	467	1.19	1.02–1.38	0.023	1.2	1.02–1.41	0.024
Unclassified	109	0.99	0.77–1.26	0.92	0.89	0.68–1.17	0.413
T stage
T3	1172	Ref.
T4	316	1.23	1.06–1.42	0.008	1.26	1.07–1.47	0.004
N stage
N1	908	Ref.
N2	390	1.66	1.43–1.92	< 0.001	1.63	1.39–1.91	< 0.001
N3	190	2.07	1.69–2.54	< 0.001	2.17	1.75–2.69	< 0.001

Models for T_1–2N⁻ and T_3–4N⁻ subgroups: adjusted for RT, age, sex, race, diagnostic time, tumor size, tumor differentiation, tumor site, number of lymph node examined, surgery type, Lauren classification, and T stage
Models for T_1–2N⁺ and T_3–4N⁺ subgroups: adjusted for adjusted for RT, age, sex, race, diagnostic time, tumor size, tumor differentiation, tumor site, number of lymph node examined, surgery type, Lauren classification, T stage, and N stage. The detailed results were shown in Supplementary Tables 1, 2, 3 and 4
RT radiation therapy, NRT neo-adjuvant radiotherapy, NOS not otherwise specific. Data are presented as hazard ratios (HRs) and 95% confidence intervals (CIs) measured by multivariable Cox regression analyses, with overall survival and cause-specific survival as the outcome, respectively

ISSN: 1471-2407